- Home
- CSR vs TYRA Comparison
CSR vs TYRA Comparison
Compare CSR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- TYRA
- Stock Information
- Founded
- CSR 1970
- TYRA 2018
- Country
- CSR United States
- TYRA United States
- Employees
- CSR N/A
- TYRA N/A
- Industry
- CSR Real Estate Investment Trusts
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- TYRA Health Care
- Exchange
- CSR Nasdaq
- TYRA Nasdaq
- Market Cap
- CSR 965.4M
- TYRA 844.2M
- IPO Year
- CSR N/A
- TYRA 2021
- Fundamental
- Price
- CSR $59.82
- TYRA $14.32
- Analyst Decision
- CSR Buy
- TYRA Strong Buy
- Analyst Count
- CSR 7
- TYRA 5
- Target Price
- CSR $68.57
- TYRA $31.20
- AVG Volume (30 Days)
- CSR 127.3K
- TYRA 266.3K
- Earning Date
- CSR 11-03-2025
- TYRA 11-05-2025
- Dividend Yield
- CSR 5.15%
- TYRA N/A
- EPS Growth
- CSR N/A
- TYRA N/A
- EPS
- CSR 1.82
- TYRA N/A
- Revenue
- CSR $273,450,000.00
- TYRA N/A
- Revenue This Year
- CSR $5.77
- TYRA N/A
- Revenue Next Year
- CSR $1.53
- TYRA N/A
- P/E Ratio
- CSR $32.79
- TYRA N/A
- Revenue Growth
- CSR 5.72
- TYRA N/A
- 52 Week Low
- CSR $52.76
- TYRA $6.42
- 52 Week High
- CSR $75.92
- TYRA $17.78
- Technical
- Relative Strength Index (RSI)
- CSR 52.57
- TYRA 49.37
- Support Level
- CSR $58.92
- TYRA $13.35
- Resistance Level
- CSR $60.87
- TYRA $15.38
- Average True Range (ATR)
- CSR 1.33
- TYRA 0.92
- MACD
- CSR -0.03
- TYRA -0.14
- Stochastic Oscillator
- CSR 59.90
- TYRA 35.37
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.